Drug intelligence / Profile preview

dipropyl-4-hydroxytryptamine

Development stage: Unknown
Modality: Small Molecules

Overview

Dipropyl-4-hydroxytryptamine is a synthetic psychedelic compound belonging to the tryptamine family. It is the 4-hydroxyl analog of dipropyltryptamine (DPT) and was first synthesized by Alexander Shulgin. The compound is structurally related to other psychedelic tryptamines, such as psilocin and DPT, but its pharmacological properties have not been fully elucidated. It is considered an experimental substance with reported psychoactive effects similar to other serotonergic psychedelics, likely acting as an agonist at serotonin receptors[1][2][7].

Other names: 3-[2-(dipropylamino)ethyl]-1H-indol-4-ol4-hydroxy-N,N-dipropyltryptamine4-hydroxydipropyltryptaminedeprocin

Targets

HTR2C (5-hydroxytryptamine 2C receptor)HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on dipropyl-4-hydroxytryptamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dipropyl-4-hydroxytryptamine.

Explore the full profile